الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 188 |  |  |
| | | from | 188 | | |
Abstract
Summary
The aim of this work was to demonstrate the extent of neuronal degeneration and axonal damage in patients with RRMS by measuring the serum level of S100B and total tau and to correlate such markers with the neurological disability status, MRI lesion load and cognitive function. We aimed also to study the impact of treating patient with RRMS with interferon beta on the serum level of S100B and total tau.
The present study was conducted on 30 patients with RRMS and 30 normal healthy controls of both sexes, with a mean age 34.16 (SD=8.34) years for patients and 32.06 (SD=6.39) years for controls. There was no statistically significant difference between patients and controls regarding age or sex.
The neurological disability and fatigue in MS patients included in our study were assessed using EDSS and MFIS respectively. The cognitive functions of MS patients were assessed using PLAT, PASAT and BVRT. These tests covered the following cognitive domains: auditory verbal memory, visual perceptual, visual memory, visual motor and visuoconstructive abilities, attention and auditory working memory.
Serum level of S100B and Tau were measured for all included patients before and 6 months after treatment with INF-B, using ELISA assay. Serum level of S100B and Tau were also measured for controls.
Theresultsofourstudyweresumarizedinthefollowing:
1. MS patients had significantly higher serum level of S100B than controls, but there was no statistically significant difference between MS patients and controls in serum Tau
2. There was a statistically significant decrease in S100B serum level in MS patients after 6 months of treatment with interferon, but there was no significant change in serum Tau.
3. MS patients had significant decrease in the scores of PLAT, BVRT, and PASAT in comparison to control.
4. There was no statistically significant correlation between age and baseline serum S100B or Tau in MS patients.
5. There was a statistically significant positive correlation between EDSS in MS patients and baseline serum S100B, but no significant correlation with baseline serum Tau.
6. There was no statistically significant correlation between disease duration or total number of relapses and either baseline serum S100B or Tau.
7. There was no statistically significant correlation between MFIS in MS patients and either baseline serum S100B or Tau.
8. There was no statistically significant correlation between the scores of PLAT, BVRT, or PASAT in MS patients, and baseline serum S100B or Tau
9. There was a statistically significant positive correlation between the number of MRI lesions in MS patients and baseline serum S100B, but no significant correlation with baseline serum Tau.